Physiol. Genomics Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Physiol. Genomics 20: 165-172, 2005. First published November 23, 2004; doi:10.1152/physiolgenomics.00120.2004
1094-8341/05 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
20/2/165    most recent
00120.2004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (11)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lonergan, T.
Right arrow Articles by Kasparov, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lonergan, T.
Right arrow Articles by Kasparov, S.
Received 21 May 2004; accepted in final form 18 November 2004.
Physiological Genomics 20:165-172 (2005)
1094-8341/05 $8.00 © 2005 American Physiological Society

Targeting brain stem centers of cardiovascular control using adenoviral vectors: impact of promoters on transgene expression

Tina Lonergan 1, Anja G. Teschemacher 2, D. Y. Hwang 3, K.-S. Kim 3, Anthony E. Pickering 1 and Sergey Kasparov 1

1 Department of Physiology, School of Medical Sciences, University of Bristol, Bristol, BS8 1TD, United Kingdom
2 Department of Pharmacology, School of Medical Sciences, University of Bristol, Bristol, BS8 1TD, United Kingdom
3 Molecular Neurobiology Laboratory, McLean Hospital, Harvard Medical School, Belmont, Massachusetts

Adenoviral vectors (AVV) are widely used as tools for exploring gene function in studies of the central autonomic control, but the cellular specificity of the promoters commonly used in these vectors has not been studied. We evaluated AVV with four "wide-spectrum" promoters, human cytomegalovirus promoter (HCMV), synapsin-1 promoter (Syn1), tubulin-{alpha}1 promoter (T{alpha}1), and neuron-specific enolase (NSE) for their ability to express enhanced green fluorescent protein (EGFP) within the dorsal vagal complex and the adjacent brain stem. They were compared with the PRSx8 promoter, specifically designed to target catecholaminergic neurons. AdHCMVEGFP, AdSyn1EGFP-WHE (woodchuck hepatitis enhancer element), AdT{alpha}1EGFP, and AdNSEEGFP were unable to drive expression of EGFP in dopamine ß-hydroxylase-immunoreactive neurons of the A2 cell group, although the adjacent dorsal vagal motonucleus and especially hypoglossal motoneurons did express high levels of EGFP. AdPRSx8EGFP efficiently drove EGFP expression in the A2 cell group but also in choline acetyltransferase-positive vagal motoneurons. However, catecholaminergic neurons could be selectively and efficiently transduced via a retrograde route by injecting the vector into their target areas. Thus AVV with "wide-spectrum" promoters have strikingly different activity in the diverse cellular populations within brain stem cardiovascular control centers. The PRSx8 promoter is a valuable tool for the study of the role of catecholaminergic neurons.

adenovirus; catecholamine; dorsal vagal complex; acetylcholine




This article has been cited by other articles:


Home page
 J. Neurosci.Home page
P. W. Howorth, S. R. Thornton, V. O'Brien, W. D. Smith, N. Nikiforova, A. G. Teschemacher, and A. E. Pickering
Retrograde Viral Vector-Mediated Inhibition of Pontospinal Noradrenergic Neurons Causes Hyperalgesia in Rats
J. Neurosci., October 14, 2009; 29(41): 12855 - 12864.
[Abstract] [Full Text] [PDF]

Home page
 Phil Trans R Soc BHome page
S. Kasparov and A. G. Teschemacher
The use of viral gene transfer in studies of brainstem noradrenergic and serotonergic neurons
Phil Trans R Soc B, September 12, 2009; 364(1529): 2565 - 2576.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
A. G. Teschemacher, S. Wang, M. K. Raizada, J. F.R. Paton, and S. Kasparov
Area-Specific Differences in Transmitter Release in Central Catecholaminergic Neurons of Spontaneously Hypertensive Rats
Hypertension, August 1, 2008; 52(2): 351 - 358.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
H. Duale, H. Waki, P. Howorth, S. Kasparov, A. G. Teschemacher, and J. F.R. Paton
Restraining influence of A2 neurons in chronic control of arterial pressure in spontaneously hypertensive rats
Cardiovasc Res, October 1, 2007; 76(1): 184 - 193.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
Z. Chiti and A. G. Teschemacher
Exocytosis of norepinephrine at axon varicosities and neuronal cell bodies in the rat brain
FASEB J, August 1, 2007; 21(10): 2540 - 2550.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
H. Waki, B. Liu, M. Miyake, K. Katahira, D. Murphy, S. Kasparov, and J. F.R. Paton
Junctional Adhesion Molecule-1 Is Upregulated in Spontaneously Hypertensive Rats: Evidence for a Prohypertensive Role Within the Brain Stem
Hypertension, June 1, 2007; 49(6): 1321 - 1327.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
H. Waki, D. Murphy, S. T. Yao, S. Kasparov, and J. F.R. Paton
Endothelial NO Synthase Activity in Nucleus Tractus Solitarii Contributes to Hypertension in Spontaneously Hypertensive Rats
Hypertension, October 1, 2006; 48(4): 644 - 650.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
A. M. Allen, J. K. Dosanjh, M. Erac, S. Dassanayake, R. D. Hannan, and W. G. Thomas
Expression of Constitutively Active Angiotensin Receptors in the Rostral Ventrolateral Medulla Increases Blood Pressure
Hypertension, June 1, 2006; 47(6): 1054 - 1061.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2005 by the American Physiological Society.